國家衛生研究院 NHRI:Item 3990099045/9143

NHRI > National Institute of Infectious Diseases and Vaccinology > Yao Chang > Periodical Articles > Item 3990099045/9143

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/9143

Title:	Kallistatin ameliorates influenza vrus pathogenesis by inhibition of kallikrein-related peptidase 1-mediated cleavage of viral hemagglutinin
Authors:	Leu, CH;Yang, ML;Chung, NH;Huang, YJ;Su, YC;Chen, YC;Lin, CC;Shieh, GS;Chang, MY;Wang, SW;Chang, Y;Chao, J;Chao, L;Wu, CL;Shiau, AL
Contributors:	Division of Infectious Diseases
Abstract:	Proteolytic cleavage of the hemagglutinin (HA) of influenza virus by host trypsin-like proteases is required for viral infectivity. Some serine proteases are capable of cleaving influenza virus HA, whereas some serine protease inhibitors (serpins) inhibit the HA cleavage in various cell types. Kallikrein-related peptidase 1 (KLK1, also known as tissue kallikrein) is a widely distributed serine protease. Kallistatin, a serpin synthesized mainly in the liver and rapidly secreted into the circulation, forms complexes with KLK1 and inhibits its activity. Here we investigated the roles of KLK1 and kallistatin in influenza virus infection. We show that the levels of KLK1 increased, whereas those of kallistatin decreased in the lung of mice during influenza infection. KLK1 cleaved H1, H2, and H3 HA molecules and consequently enhanced viral production. By contrast, kallistatin inhibited KLK1-mediated HA cleavage and reduced viral production. Cells transduced with the kallistatin gene secreted kallistatin extracellularly, which rendered them more resistant to influenza virus infection. Furthermore, lentivirus-mediated kallistatin gene delivery protected mice against lethal influenza virus challenge by reducing viral load, inflammation, and injury in the lung. Taken together, we identify that KLK1 and kallistatin contribute to the pathogenesis of influenza virus by affecting the cleavage of the HA peptide and inflammatory responses. This study provides a proof of principle for the potential therapeutic application of kallistatin or other KLK1 inhibitors for influenza. Since proteolytic activation also enhances the infectivity of some other viruses, kallistatin and other kallikrein inhibitors may be explored as antiviral agents against these viruses.
Date:	2015-09
Relation:	Antimicrobial Agents and Chemotherapy. 2015 Sep;59(9):5619-5630.
Link to:	http://dx.doi.org/10.1128/aac.00065-15
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0066-4804&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000364343900066
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84940915672
Appears in Collections:	[Yao Chang] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB26149981.pdf		3195Kb	Adobe PDF	494	View/Open

Loading...